Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.40 |
| ▸ | TYR | P14679 | 6/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21469698 | 0.86 | FOLH1 (0.38) | FOLH1TYRTGM2SIRT2SIRT1 | |
| SCHEMBL18476659 | 0.86 | TGM2 (0.44) | FOLH1TYRTGM2SIRT2SIRT1 | |
| SCHEMBL23627653 | 0.83 | FOLH1 (0.36) | FOLH1TYRTGM2SIRT2SIRT1 | |
| SCHEMBL20465446 | 0.83 | FOLH1 (0.36) | FOLH1TYRTGM2SIRT2SIRT1 | |
| SCHEMBL20465441 | 0.83 | FOLH1 (0.36) | FOLH1TYRTGM2SIRT2SIRT1 | |
| SCHEMBL19628966 | 0.82 | FOLH1 (0.36) | FOLH1TYRTGM2SIRT2SIRT1 | |
| SCHEMBL18650384 | 0.82 | TYR (0.37) | FOLH1TYRTGM2ITGB3ITGAV | |
| SCHEMBL18631756 | 0.82 | TYR (0.37) | FOLH1TYRTGM2ITGB3ITGAV | |
| SCHEMBL18451517 | 0.79 | FOLH1 (0.33) | FOLH1TYRTGM2SIRT2SIRT1 | |
| SCHEMBL18631761 | 0.75 | PSMB11 (0.35) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926640-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11926640-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | FOLH1 403/4885TYR 2744/4885TGM2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.